A total of 2,291 patients with drug-eluting stent implantation for ACS or SAP (n = 1,804) who underwent noncardiac surgery were compared with a cohort from the general population without known coronary artery disease. The patients were matched according to the surgical procedure, hospital contact type, gender, and age. The 30-day MI risk markedly increased when surgery was performed within 1 month after stenting, in patients with acute coronary syndrome (10% vs 0.8%; adjusted odds ratio [ORadj] 20.1, 95% confidence interval [CI] 8.85 to 45.6). The mortality, however, was comparable (10% vs 8%, ORadj 1.17, 95% CI 0.76 to 1.79). The 30-day absolute risk for MI was low but higher than in the comparison cohort (0.6% vs 0.2%, ORadj 2.18, 95% CI 0.89 to 5.38), when surgery was performed between 1 and 12 months after stenting. The mortality risks were similar (2.0% vs 1.8%, ORadj 1.03, 95% CI 0.69 to 1.55). The 30-day MI risk was low but higher than in the comparison cohort (0.4% vs 0.2%, ORadj 1.90, 95% CI 0.70 to 5.14), in patients with SAP. However, the mortality risks were similar However, the mortality risks were similar (2.2% vs 2.1%, ORadj 0.91, 95% CI 0.61 to 1.37).

Patients with acute coronary syndrome and stable angina pectoris who underwent surgery between 1- and 12-months following stent implantation had a risk for MI and death similar to the risk observed in surgical patients without coronary artery disease.


acute coronary syndrome,myocardial infarction,coronary artery disease,percutaneous coronary intervention




Disease Condition ,Therapeutic Modality ,Coronary Artery Disease,Interventional Cardiology,Acute Coronary Syndrome,Myocardial Infarction,Percutaneous Coronary Intervention